Compare DexCom, Inc. (DXCM) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Southwest Airlines Co — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while Southwest Airlines Co trades at $49.21 (market cap $24.07B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Southwest Airlines Co pays a 1.46% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LUV | |
|---|---|---|
Market Cap | $28.06B | $24.07B |
Sector | Health | Industrials |
52-Week High | $89.53 | $54.80 |
52-Week Low | $54.84 | $29.06 |
Enterprise Value | $27.03B | $27.14B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Southwest Airlines (LUV) trades at $47.56, down 0.75% on the day, with a mixed technical picture showing bullish signals from moving averages and oscillators but near-term support at $47. Fundamentally, the company reported revenue of $28.06B for 2025 with a net income margin of 2.83%, though earnings missed expectations in Q1 2026. Recent news highlights upcoming Q2 2026 earnings on July 23, 2026, with analysts focused on travel demand and fuel cost pressures.
The investment outlook balances transformation initiatives and resilient travel demand against significant fuel price volatility and execution risks. Analyst consensus is mixed with a $52.47 price target, representing ~10% upside, but risks include lack of fuel hedging and competitive pressures. The stock's valuation at a P/E of 32.83 appears elevated relative to historical airline multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
